Apr 14, 2023
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D.
Mar 27, 2023
SAN DIEGO --(BUSINESS WIRE)--Mar. 27, 2023-- As previously announced on March 21, 2023 , Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the closing of its business combination with